We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Health Agencies Update |

Sepsis Drug Risks

Bridget M. Kuehn
JAMA. 2009;301(12):1217. doi:10.1001/jama.2009.374.
Text Size: A A A
Published online


Reports of serious bleeding and deaths among patients treated for severe sepsis with a recombinant form of human activated protein C, drotrecogin alfa, have prompted the US Food and Drug Administration (FDA) to evaluate these safety concerns, according to an early communication from the agency.

According to the FDA, after a recent retrospective study suggested that patients with severe sepsis and certain concurrent risk factors for bleeding may be more likely than patients without such risk factors to experience serious bleeding when taking drotrecogin alfa activated, the agency and the drug maker decided to reevaluate the potential problems associated with this drug. A review of the medical records of 73 patients who were treated with drotrecogin alfa activated found that serious bleeding occurred in 7 of the 20 patients (35%) who had a concurrent elevated risk of bleeding compared with 2 of 53 patients (3.8%) without these factors (Gentry CA et al. Crit Care Med. 2009;37[1]:19-25). Patients with bleeding risk factors also were more likely to die; 13 of the 20 such patients (65%) died of any cause compared with 13 of 53 (24.5%) of those without such factors.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Update in Critical Care 2015. Am J Respir Crit Care Med 2016;194(1):19-25.